<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887120</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT045</org_study_id>
    <nct_id>NCT00887120</nct_id>
  </id_info>
  <brief_title>Dose Reduction of Lopinavir in Children</brief_title>
  <official_title>Pharmacokinetics and Efficacy of Low- or Standard-Dose of Lopinavir/Ritonavir (Kaletra速) in PI-na誰ve HIV-1 Infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the pharmacokinetics of low-dose and standard dose, lopinavir/ritonavir in ARV PI
      naive HIV-1 infected Thai children.

      To study clinical and immunological efficacy after 48 weeks of lopinavir/ritonavir in PI
      na誰ve HIV-1 infected Thai children
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2002, the Thai Ministry of Public Health (MOPH) launched the National Access to
      Antiretroviral Program for People living with HIV/AIDS (NAPHA) with the aim of providing
      treatment to all Thai patients who needed antiretroviral treatment. By the end of 2005,
      80,000 HIV-infected Thais were treated in the NAPHA program, including about 6,000 children.
      The antiretroviral treatment regimen consists of three antiretroviral drugs (ARV). The
      first-line regimen used in NAPHA are mainly generic drugs produced by Thai government
      pharmaceutical organization (GPO), including a fixed-drug combination of stavudine,
      lamivudine, and nevirapine (GPOvir);and a fixed-drug combination of zidovudine, lamivudine,
      and nevirapine (GPOvir-Z). Majority of patients respond very well with first-line
      regimen(1,2), however about 15% of patients have drug resistance to first-line regimen and
      require second-line regimen(3). The protease inhibitors (PIs) is used as a second-line
      regimen, however there are limitations in terms of cost and metabolic complications(4).

      Lopinavir/ritonavir is the most widely use protease inhibitors in children because of its
      high efficacy and a syrup formulation that easy to use in small children. There is evidence
      supported that the recommended dose according to US-FDA or EU guidelines resulting in much
      higher plasma blood level in Thai children. Data from 19 Thai children demonstrated Cmin of
      5.9 mg/L compare to 3.4 mg/L in US children when use the same dose (the minimum acceptable
      Cmin is 1.0 mg/L) (5,6). There is a study HIVNAT019, which demonstrated acceptable LPV plasma
      concentration and treatment outcome in Thai HIV-infected adult when use reduced dose of LPV/r
      266mg/66 mg compare to standard dose of 400mg/100mg (7).

      Therefore, the study of pharmacokinetic of low dose of LPV/r in Thai HIV-infected children is
      very important to assess the safety and efficacy of this strategy. This will lead to
      appropriate ARV dose in children to reduce long-term adverse events, and also reduce the ARV
      cost.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics of standard vs low dose LPV/r</measure>
    <time_frame>4 weeks after start ART</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy and safety of standard and low dose LPV/r</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir/ritonavir standard dose + zidovudine and lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir standard dose According to WHO simplified dosing table</intervention_name>
    <description>BW 6-7.9 kg: 1.5 mL oral q 12 hr
BW 8.0-16.9 kg: 2.0 ml oral q 12 hr
BW 17.0-19.9 kg: 2.5 ml oral q 12 hr
BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr
BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr
BW 30.0-34.9 kg: 4.0 ml oral q 12 hr
BW &gt; 35 kg: 5.0 ml oral q 12 hr
Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)</intervention_name>
    <description>BW 6-7.9 kg: 1.0 mL oral q 12 hr
BW 8.0-16.9 kg: 1.5 ml oral q 12 hr
BW 17.0-19.9 kg: 1.8 ml oral q 12 hr
BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr
BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr
BW 30.0-34.9 kg: 3.0 ml oral q 12 hr
BW &gt; 35 kg: 3.5 ml oral q 12 h
Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 2- 18 years old

          -  Documented positive test for HIV-1 infection

          -  PI-na誰ve

          -  HIV RNA viral load &gt; 1,000 copies

          -  Written informed consent

        Exclusion Criteria:

          -  Active opportunistic infection

          -  Relevant history or current condition, illness that might interfere with drug
             absorption, distribution, metabolism or excretion.

          -  Use of concomitant medication that may interfere with the pharmacokinetics of
             lopinavir/ritonavir

          -  Pregnancy or lactating

          -  Inability to understand the nature and extent of the study and the procedures
             required.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Faculty of Medicine, Chulalongkorn University and Thai Red Cross Aids Research Centre - HIV-NAT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>April 22, 2009</last_update_submitted>
  <last_update_submitted_qc>April 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kiat Ruxrungtham</name_title>
    <organization>Department of Medicine, Faculty of Medicine, Chulalongkorn University and Thai Red Cross Aids Research Centre - HIV-NAT</organization>
  </responsible_party>
  <keyword>Second line treatment</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <keyword>Asia</keyword>
  <keyword>LPV</keyword>
  <keyword>children</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>To study the pharmacokinetics of low-dose and standard dose, lopinavir/ritonavir in Protease inhibitor (PI)- naive HIV-1 infected Thai patients.</keyword>
  <keyword>To study clinical and immunological efficacy after 48-weeks of lopinavir/ritonavir-based antiretroviral therapy in PI naive HIV-1 infected Thai patients.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

